A research roundup covering major themes in peptide and longevity science for Q2 2026 — GLP-1 receptor agonist expansion, GH peptide research, senolytic compounds, NAD+ clinical data, AI-assisted peptide design, and the evolving regulatory landscape for research peptides.

Comprehensive research guide to building an NAD+ boosting stack — covering NMN vs NR vs niacin pathways, TMG for methylation balance, resveratrol and sirtuin activation, AMPK agonists (Berberine), timing considerations, and monitoring via NAD+ blood testing.

Research overview of oxaloacetate (OAA) as a longevity and metabolic compound — its role as a Krebs cycle intermediate, NAD+ precursor effects, caloric restriction mimetic properties, AMPK activation, neuroprotection, and research on anhydrous oxaloacetate (benaGene) at 100-300mg/day.

Comprehensive research comparison of all NAD+ precursor pathways — NMN, NR, sublingual NMN, IV NAD+, and niacin — covering biosynthesis routes (Preiss-Handler, salvage, de novo pathways), bioavailability research, tissue distribution, and cost-per-dose analysis.

Research comparison of IV NAD+, NMN, NR, and sublingual routes — covering bioavailability, PARP enzyme substrate, sirtuin activation, mitochondrial biogenesis, IV flush effects, and typical clinical protocols from 500–1500mg.